Home  |  Site Map  |  Glossary  | Contact
February 28 QLT Announces Fourth Quarter and Year End 2013 Results
February 27 QLT Announces Positive Preliminary Results from Phase 1b Retreatment Trial of QLT091001 in Subjects with Leber Congenital Amaurosis and Retinitis Pigmentosa Due to Mutations in LRAT or RPE65
December 9 QLT Announces First Patient Dosed in Phase IIa Proof-of-Concept Trial for QLT091001 in Impaired Dark Adaptation
Copyright 2000-2009 QLT Inc. Legal Terms for use of site and Privacy Policy | Disclaimer
Vancouver Web Design by Graphically Speaking
Employee Login